Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.40 |
| ▸ | RPA1 | P27694 | 8/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | MARS1 | P56192 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267029 | 0.93 | GSK3B (0.38) | BCL2GSK3BDYRK1AALOX5FYN | |
| SCHEMBL5267396 | 0.87 | RPA1 (0.44) | BCL2RPA1GSK3BDYRK1AMDM2 | |
| SCHEMBL5270809 | 0.87 | GSK3B (0.35) | BCL2RPA1GSK3BDYRK1AMDM2 | |
| SCHEMBL5267510 | 0.85 | GABRA1 (0.38) | BCL2GSK3BDYRK1AALOX5 | |
| SCHEMBL5268373 | 0.80 | RPA1 (0.45) | BCL2RPA1MDM2MCL1MARS1 | |
| SCHEMBL5266650 | 0.80 | GSK3B (0.35) | BCL2GSK3BDYRK1AALOX5 | |
| SCHEMBL5266512 | 0.79 | KDM4E (0.42) | BCL2RPA1DYRK1AMDM2MCL1 | |
| SCHEMBL5526472 | 0.77 | GPR119 (0.38) | BCL2RPA1GSK3BDYRK1AMDM2 | |
| SCHEMBL5269108 | 0.77 | CA9 (0.43) | BCL2FYN | |
| SCHEMBL5522419 | 0.76 | GSK3B (0.32) | GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | BCL2 3162/4885RPA1 1150/4885GSK3B 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.